Drug Profile


Alternative Names: Acardi; UDCG 115; UDCG 115A; UDCG 115BS

Latest Information Update: 07 Sep 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Developer Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
  • Class Cardiotonics; Pyridazines; Small molecules
  • Mechanism of Action Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Heart failure
  • Discontinued Ischaemic heart disorders

Most Recent Events

  • 07 Sep 2009 Discontinued for Heart failure in Australia (PO)
  • 07 Sep 2009 Discontinued for Heart failure in European Union (PO)
  • 07 Sep 2009 Discontinued for Heart failure in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top